GSK PLC Sponsored ADR $GSK Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. grew its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 51.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,653 shares of the pharmaceutical company’s stock after buying an additional 21,400 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in GSK were worth $2,957,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GSK. NewEdge Advisors LLC grew its position in shares of GSK by 842.9% during the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after buying an additional 852,437 shares in the last quarter. Sound Income Strategies LLC increased its stake in shares of GSK by 2.7% in the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock worth $16,209,000 after buying an additional 9,218 shares during the last quarter. Waverly Advisors LLC increased its stake in shares of GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock worth $15,233,000 after buying an additional 270,863 shares during the last quarter. Tidal Investments LLC increased its stake in shares of GSK by 4.6% in the second quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock worth $11,545,000 after buying an additional 9,603 shares during the last quarter. Finally, Keystone Financial Planning Inc. raised its holdings in GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock valued at $10,253,000 after acquiring an additional 189,506 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on GSK. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Royal Bank Of Canada assumed coverage on shares of GSK in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. JPMorgan Chase & Co. reissued a “sell” rating on shares of GSK in a research report on Thursday, October 1st. The Goldman Sachs Group reissued a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Finally, HSBC restated a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $55.33.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) for adults with locally advanced rectal cancer characterized by MSI-H or dMMR biomarkers. The approval expands Jemperli’s commercial opportunity and strengthens GSK’s position in biomarker-driven cancer treatment. GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
• Positive Sentiment: U.S. regulators approved GSK’s hepatitis B drug, offering eligible patients the possibility of stopping long-term treatment. The product could address a significant unmet need and create a new growth driver if adoption is strong. US FDA approves GSK’s hepatitis B drug
• Positive Sentiment: GSK reported encouraging early data for experimental lung cancer therapy risvutatug rezetecan. The drug produced a 61% confirmed response rate at the 8 mg/kg dose in relapsed extensive-stage small-cell lung cancer, compared with 32% at the lower dose. The results improve the drug’s potential value, although the trial remains early-stage. GSK lung cancer drug shows 61% response rate in early global trial
• Positive Sentiment: Jefferies maintained a “buy” rating and set a 2,500-pence price target, citing the lung cancer data and potential upside for GSK. The endorsement reinforces investor confidence in the company’s pipeline. Jefferies backs GSK with 2,500p target
• Neutral Sentiment: Analysts have highlighted GSK’s newer medicines, expanded indications and pipeline as potential drivers of long-term sales growth, but much of that outlook depends on successful late-stage development, regulatory approvals and commercial execution.

GSK Trading Up 2.3%

NYSE:GSK opened at $50.60 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The business’s 50 day moving average is $49.55 and its two-hundred day moving average is $51.54. GSK PLC Sponsored ADR has a 52 week low of $42.85 and a 52 week high of $61.69. The company has a market cap of $102.34 billion, a PE ratio of 15.82, a P/E/G ratio of 2.23 and a beta of 0.33.

GSK (NYSE:GSK) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. During the same quarter last year, the firm earned $0.47 EPS. The business’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Friday, August 14th were paid a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. GSK’s dividend payout ratio (DPR) is 55.31%.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.